US WorldMeds
US WorldMeds is a healthcare company that develops, licenses, and markets products for challenging medical conditions, including IWILFIN™ for neuroblastoma and LUCEMYRA® for opioid withdrawal.
Company Overview
US WorldMeds develops, licenses, and markets healthcare products focused on improving the lives of patients with challenging conditions and unmet medical needs. The company's product line addresses high-risk neuroblastoma, opioid withdrawal, and malignant hyperthermia. US WorldMeds is also actively engaged in research and development activities, including conducting clinical trials and offering grants.
Products
US WorldMeds offers several key products aimed at treating serious medical conditions. IWILFIN™ (eflornithine) tablets are used to treat high-risk neuroblastoma. LUCEMYRA® (lofexidine) tablets assist with managing opioid withdrawal symptoms. Revonto® (dantrolene sodium for injection) is used for the treatment of malignant hyperthermia.
Research and Development
US WorldMeds is dedicated to ongoing research and development efforts, which include clinical trials and granting funding to support innovative medical research. The company's work in R&D aims to bring new therapeutic options to market and to advance medical science in areas of significant unmet need.
Compliance and Ethical Conduct
US WorldMeds is committed to operating ethically and in compliance with all relevant laws. The company has a comprehensive compliance program administered by a designated Compliance Officer. Additionally, as part of regulatory compliance, US WorldMeds adheres to the Unwanted Medicine and Sharps program(s) of MED-Project USA and maintains annual spending limits on promotional activities directed toward healthcare professionals in California.
Expanded Access Programs
US WorldMeds provides investigational drugs outside of clinical trials in certain situations through Expanded Access programs, also known as 'compassionate use'. These programs are designed to make unapproved therapies available to patients with serious or immediately life-threatening conditions when no comparable or satisfactory alternative therapy options are available.